Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 292

1.

Treatment options for relapsed and refractory multiple myeloma.

Lonial S, Mitsiades CS, Richardson PG.

Clin Cancer Res. 2011 Mar 15;17(6):1264-77. doi: 10.1158/1078-0432.CCR-10-1805. Review.

2.

Treatment of relapsed and refractory myeloma.

Kaufman J, Gleason C, Lonial S.

Curr Hematol Malig Rep. 2009 Apr;4(2):99-107. doi: 10.1007/s11899-009-0014-5. Review.

PMID:
20425421
3.

Novel agents for relapsed and/or refractory multiple myeloma.

Thomas SK, Richards TA, Weber DM.

Cancer J. 2009 Nov-Dec;15(6):485-93. doi: 10.1097/PPO.0b013e3181c51cba. Review.

PMID:
20010168
4.

Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.

Schmielau J, Teschendorf C, König M, Schmiegel W, Graeven U.

Leuk Lymphoma. 2005 Apr;46(4):567-9.

PMID:
16019485
5.

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.

Palumbo A, Attal M, Roussel M.

Clin Cancer Res. 2011 Mar 15;17(6):1253-63. doi: 10.1158/1078-0432.CCR-10-1925. Review.

6.

Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.

Morgan G.

Blood Rev. 2010 Nov;24 Suppl 1:S27-32. doi: 10.1016/S0268-960X(10)70006-0.

PMID:
21126634
7.

The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.

Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Redman KC, McKenney M, Warren D, Noonan K, Lunde L, Doss D, Colson K, Hideshima T, Mitsiades C, Munshi NC, Anderson KC.

Eur J Haematol. 2012 May;88(5):446-9. doi: 10.1111/j.1600-0609.2012.01765.x. Epub 2012 Mar 7.

PMID:
22300348
8.

The emerging role of novel therapies for the treatment of relapsed myeloma.

Richardson PG, Hideshima T, Mitsiades C, Anderson KC.

J Natl Compr Canc Netw. 2007 Feb;5(2):149-62. Review.

PMID:
17335684
9.

The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.

Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M.

Eur J Haematol. 2010 Dec;85(6):484-91. doi: 10.1111/j.1600-0609.2010.01526.x.

PMID:
20846301
10.

[Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].

Takeda Y, Sakaida E, Nakaseko C.

Nihon Rinsho. 2015 Jan;73(1):130-6. Japanese.

PMID:
25626318
11.

Management of relapsed and relapsed refractory myeloma.

Kastritis E, Mitsiades CS, Dimopoulos MA, Richardson PG.

Hematol Oncol Clin North Am. 2007 Dec;21(6):1175-215, x. Review.

PMID:
17996594
12.

Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.

Delforge M, Michiels A, Doyen C, Kentos A, Van Droogenbroeck J, Offner F, Bries G, Demuynck H, Vekemans MC, Meuleman N, Mineur PO, Ravoet C, Depryck B, Van de Velde A, Pierre P, Wu KL, Schots R.

Acta Clin Belg. 2011 Sep-Oct;66(5):371-5.

PMID:
22145272
13.

"IM iD"eally treating multiple myeloma.

Lacy MQ.

Blood. 2013 Mar 14;121(11):1926-8. doi: 10.1182/blood-2013-01-476267.

14.

Treatment of multiple myeloma in the targeted therapy era.

Saad AA, Sharma M, Higa GM.

Ann Pharmacother. 2009 Feb;43(2):329-38. doi: 10.1345/aph.1L428. Epub 2009 Feb 3. Review.

PMID:
19193585
15.

Advances in treatment for relapses and refractory multiple myeloma.

Richards T, Weber D.

Med Oncol. 2010 Jun;27 Suppl 1:S25-42. doi: 10.1007/s12032-009-9407-5. Epub 2010 Mar 6. Review.

PMID:
20213220
16.

An update on drug combinations for treatment of myeloma.

Srikanth M, Davies FE, Morgan GJ.

Expert Opin Investig Drugs. 2008 Jan;17(1):1-12. Review.

PMID:
18095914
17.

Advances in therapy of multiple myeloma.

Bladé J, Rosiñol L.

Curr Opin Oncol. 2008 Nov;20(6):697-704. doi: 10.1097/CCO.0b013e3283136984. Review.

PMID:
18841053
18.

A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.

Ahn JS, Yang DH, Jung SH, Park HC, Moon JH, Sohn SK, Bae SY, Kim YK, Kim HJ, Lee JJ; Korean Multiple Myeloma Working Party (KMMWP)..

Ann Hematol. 2012 Jul;91(7):1023-30. doi: 10.1007/s00277-012-1420-7.

PMID:
22314843
19.

Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?

Ludwig H, Sonneveld P.

Leuk Res. 2012 Nov;36 Suppl 1:S27-34. doi: 10.1016/S0145-2126(12)70006-1. Review.

PMID:
23176721
20.

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.

Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A, Munshi NC, Ghobrial IM, Doss D, Warren DL, Lunde LE, McKenney M, Delaney C, Mitsiades CS, Hideshima T, Dalton W, Knight R, Esseltine DL, Anderson KC.

J Clin Oncol. 2009 Dec 1;27(34):5713-9. doi: 10.1200/JCO.2009.22.2679. Epub 2009 Sep 28.

Supplemental Content

Support Center